ARGX

argenx SE - ADR

984.04

USD

-18.27

-1.82%

Sep 10, 15:59 UTC -4

Closed

After-Market

987.47

+3.43

+0.35%

argenx SE - ADR Profile

About

argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.

Info & Links

CEO

Tim Van Hauwermeiren

Headquarters

LAARDERHOOGTWEG 25
AMSTERDAM, P7 1101EB, NETHERLANDS

Auditor

Deloitte Accountants B.V.

Share holders

Employees

1,863

argenx SE - ADR Statistics

Valuation Measures

Market Capitalization²

61.78B

Enterprise Value

58.19B

Enterprise Value/EBITDA(ttm)

36.33

Price to Earnings Ratio(ttm)

38.67

Price to Sales(ttm)

11.82

Price to Book(mrq)

7.49

Price to Cash(ytd)

47.21

Profitability

Gross Margin(ttm)

90.15%

Operating Margin(ttm)

32.19%

Profit Margin(ttm)

32.19%

Return on Equity(ttm)

43.59%

Return on Invested Capital(ttm)

12.91%

Return on Assets(ttm)

36.66%

Income Statement

Revenue(ttm)

5.33B

Revenue Per Share(ttm)

Gross Profit(ttm)

4.80B

EBITDA(ttm)³

1.60B

Net Income Available to Common(ttm)

1.72B

Diluted EPS(ttm)

26.04

Share Statistics

Beta (5Y Monthly)

0.47

52-Week Change

28.30%

S&P 500 52-Week Change

17.72%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

Dividend Yield

0.00%

Float⁴

61.04M

% Held by Insiders

2.43%

% Held by Institutions

60.32%

Balance Sheet

Total Cash(mrq)

3.58B

Total Cash Per Share(mrq)

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

5.12%

Quick Ratio(mrq)

4.89%

Book Value Per Share(mrq)

134.59

Cash Flow

Operating Cash Flow Per Share(ytd)

10.09

Free Cash Flow(ytd)

648.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.